Skip to Content

Opulis

Active Substance: desloratadine
Common Name: desloratadine
ATC Code: R06AX27
Marketing Authorisation Holder: Schering-Plough Europe
Active Substance: desloratadine
Status: Withdrawn
Authorisation Date: 2001-01-15
Therapeutic Area: Urticaria Rhinitis, Allergic, Seasonal Rhinitis, Allergic, Perennial
Pharmacotherapeutic Group: Antihistamines for systemic use

Therapeutic Indication

Opulis is indicated for the relief of symptoms associated with:
- allergic rhinitis (see section 5.1)
- urticaria (see section 5.1)

The marketing authorisation for Opulis has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide